Compare PKG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKG | BIIB |
|---|---|---|
| Founded | 1867 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 24.2B |
| IPO Year | 2000 | 1991 |
| Metric | PKG | BIIB |
|---|---|---|
| Price | $198.35 | $181.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 23 |
| Target Price | ★ $233.43 | $176.48 |
| AVG Volume (30 Days) | 739.3K | ★ 1.9M |
| Earning Date | 01-27-2026 | 10-30-2025 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | 9.90 | ★ 10.97 |
| Revenue | $8,771,800,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $9.43 | $3.61 |
| Revenue Next Year | $13.27 | N/A |
| P/E Ratio | $20.05 | ★ $16.52 |
| Revenue Growth | ★ 7.30 | 4.77 |
| 52 Week Low | $172.72 | $110.04 |
| 52 Week High | $245.87 | $185.17 |
| Indicator | PKG | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 47.80 | 72.92 |
| Support Level | $191.65 | $174.53 |
| Resistance Level | $205.68 | $182.94 |
| Average True Range (ATR) | 4.48 | 5.22 |
| MACD | 0.28 | 0.25 |
| Stochastic Oscillator | 48.31 | 83.54 |
Packaging Corp. of America is the third-largest containerboard and corrugated packaging manufacturer in the United States. It produces over 5 million tons of containerboard annually. The company's share of the domestic containerboard market is roughly 10%. PCA differentiates itself from larger competitors by focusing on smaller customers and operating with a high degree of flexibility.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).